PMID- 19999115
OWN - NLM
STAT- MEDLINE
DCOM- 20100119
LR  - 20201209
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 67
IP  - 12
DP  - 2009 Dec
TI  - [Second-line therapy for patients with Helicobacter pylori eradication failure].
PG  - 2297-302
AB  - Meta-analyses showed that quadruple therapy, ranitidine bismuth-based triple 
      therapy and levofloxacin-based triple therapy were the most effective for the 
      second-line H. pylori eradication therapy. In Japan, many studies showed that 
      triple therapy with proton pump inhibitor (PPI), amoxicillin (AMPC) and 
      metronidazole was effective after eradication failure using triple therapy with 
      PPI, AMPC and clarithromycin. The intention-to-treat eradication rates were 
      81-97%, and the incidence rates of adverse events were 8-33%.
FAU - Satoh, Kiichi
AU  - Satoh K
AD  - Division of Gastroenterology, Department of Internal Medicine, Jichi Medical 
      University.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
SB  - IM
MH  - Drug Therapy, Combination
MH  - Helicobacter Infections/*drug therapy/microbiology
MH  - *Helicobacter pylori/drug effects
MH  - Humans
RF  - 37
EDAT- 2009/12/17 06:00
MHDA- 2010/01/20 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/01/20 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2009 Dec;67(12):2297-302.